Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran PK in Renal Impairment
NCT06589713Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of enpatoran in systemic lupus erythematosus (SLE) (2 arms), sponsored by Merck KGaA. Primary endpoint: Pharmacokinetic Plasma Concentrations of Enpatoran at 48 hours. Started Sep 2024; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06589713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06589713.